112 results about "Tofacitinib" patented technology

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.

The invention belongs to the field of medicine preparations, and particularly relates to a tofacitinib tablet and a preparation method thereof. Direct-pressed lactose and microcrystalline cellulose with good mobility and compression formability are selected by the tablet as a diluent and a drying adhesive. The tablet is prepared by direct powder compression method. The tablet is simple in technology, time-saving and energy-saving; the prepared tofacitinib composition is controllable in quality; and the stability of the product is ensured.

The invention discloses a preparation method of JAKs inhibitor drug tofacitinib, which is characterized in that it comprises the following steps: (1) using 2,4-dichloro-7H pyrrole [2,3-D] pyrimidine as a raw material, Under the action of base, react with halobenzyl to prepare compound II; (2) (3R,4R)-N,4-dimethyl-1-(phenylmethyl)-3-piperidinamine hydrochloride React with 7-benzyl-2,4-dichloro-7H pyrrole [2,3-D] pyrimidine under the action of a base to prepare compound IV; (3) the compound IV obtained in step (2) is catalyzed under the action of a metal catalyst Hydrogenation reaction to obtain compound V; (4) Compound V obtained in step (3) is coupled and docked with cyanoacetic acid under the action of a condensing agent to obtain compound VI; (5) Compound VI obtained in step (4) is prepared by salting with citric acid Get tofacitinib. The synthesis route of the method is short, the reaction process of each step is easy to operate, the solvent can be recycled and used mechanically, the pollution is small, and it is suitable for large-scale industrial production.

The invention discloses a tofacitinib intermediate, a crystal form and a preparation method thereof, the tofacitinib intermediate is a compound shown as a formula VI. The positions of characteristic diffraction peaks of the intermediate in an X-ray powder diffraction pattern when the reflection angle 2theta is about 7.4 DEG, 10.0 DEG, 11.8 DEG, 14.6 DEG, 16.3 DEG, 19.0 DEG, 19.3 DEG, 20.5 DEG, 23.8 DEG, 24.2 DEG, 25.2 DEG, 25.8 DEG, 26.0 DEG, 27.0 DEG, 28.0 DEG, 28.3 DEG, 28.9 DEG, 29.3 DEG, 31.2 DEG, 31.7 DEG, 32.1 DEG, 34.4 DEG and 38.2 DEG. The formula VI compound is stable and easy to store and transport.

The invention discloses an industrial production method of citric acid tofacitinib. The method comprises the following steps: (1) adding a compound SMA and a compound SMB to a mixed solvent 1 which comprises DMSO and purified water, and catalyzing through DIPEA to react to obtain an intermediate INA; (2) carrying out a homogeneous reaction of the INA under an alkaline condition to obtain a rough intermediate INB; (3) refining the rough INB through low-level alcohol and water to obtain fine INB; (4) treating the fine INB by debenzylation and acidification to obtain an intermediate INC (salt form); (5) carrying out a reaction between the INC and SMC to obtain an intermediate IND which is tofacitinib free alkali; (6) preparing salt through the IND and citric acid monohydrate in purified waterto obtain citric acid tofacitinib. According to the method, the defects of preparation technologies in existing literatures can be solved; the used solvents are three types of solvents, so that the environmental pollution is low; the time consumption is small; the operation processes are simple; industrial production can be carried out. The formula is shown in the description.

The invention discloses a tofacitinib coating tablet with excellent property. The coating tablet comprises a coating basic reagent, tofacitinib and an officinal additive, wherein the coating basic reagent is in a coating layer of the coating tablet and selected from polyvinyl alcohol and Pullulan; and the proportion (wt/wt) of the contents of the polyvinyl alcohol to the Pullulan in the coating tablet is 1: 1-1: 5. The coating tablet is excellent in mechanical property, high in stability, convenient in pharmacy, rapid in effect and efficient.

The invention discloses a tofacitinib controlled release tablet, a preparation method and application of the tofacitinib controlled release tablet. The tofacitinib controlled release tablet consists of a medicine-containing tablet core and a controlled release coating film, wherein the medicine-containing tablet core contains a tofacitinib raw material and an auxiliary material; and the controlledrelease coating film contains a film-forming material, a pore-forming agent and/or an excipient. The preparation process of the tofacitinib controlled release tablet requires no laser drilling or special precision equipment, and is simple, easy to implement, low in production cost and short in period, and no organic solvent is used in a coating liquid preparation process, so that adverse effectson the human body and the environment are avoided, and the preparation process is suitable for industrial production.

A topical formulation comprising (a) a therapeutically effective amount of tofacitinib; (b) at least one solvent; and (c) optionally one or more other pharmaceutically acceptable excipients is provided. Also provided is a method for treating and/or preventing autoimmune diseases in a subject administering said topical formulation.

The invention provides a N-methyl-N((3R,4R)-4-methyl piperidine-3-group)-7H-pyrrolo[2,3-D]pyrimidine-4-amine (tofacitinib intermediate)preparation method and a method for preparing tofacitinib or its salt by using the tofacitinib intermediate preparation method. The tofacitinib intermediate preparation method can dissolve a compound in a formula (II) in a mixed solvent system of an acidic solvent and an organic solvent, and then a hydrogenation reaction is carried out under existence of palladium carbon or platinum carbon catalyst, thereby a compound in a formula (1) can be obtained. The method is simple to operate, and the tofacitinib intermediate yield is high. The invention also relates to the compound in the formula (1) prepared by the method and tofacitinib or its medicinal salt prepared by the compound.

The invention discloses a preparation method of a tofacitinib intermediate compound-1-benzyl-3-methyl amino-4-methyl piperidine dihydrochloride. The method comprises the following steps: (1) carrying out selective deprotection on a compound as shown in a structural formula (V) to synthesize a compound-1-benzyl-3-amino-4-methyl piperidine as shown in a structural formula (VI); (2) enabling the compound as shown in the structural formula (VI) to have a primary amine monomethylation reaction to generate the target compound-1-benzyl-3-methyl amino-4-methyl piperidine dihydrochloride as shown in a structural formula (I). The method has the characteristics of being easy in obtaining of raw materials, novel in route, less in by-products, simple and convenient to operate, high in yield, and the like.

The invention belongs to the field of medicine and particularly relates to a new method for preparing a citric acid tofacitinib medicinal crystal form. The method has the advantages of being simple inoperation, good in reproducibility, high in yield, good in purifying effect for API related substances, high in crystal form purity, suitable for industrialized mass production and the like, and overcomes the problems of complicated operation, low reproducibility, low yield, poor purifying effect for API related substances, low crystal form purify, unsuitability for industrialized production andthe like.

The invention relates to a synthesis method for tofacitinib serving as a JAK inhibitor. According to the method, the tofacitinib is prepared by taking (4-picoline-3-yl)methyl carbamate as a raw material, and performing catalytic hydrogenation, benzyl protection, reduction, salification, separation, deprotection and amidation salification. The method specifically comprises the following steps: (1) performing catalytic hydrogenation and reduction on (4-picoline-3-yl)methyl carbamate in sulfuric acid and Pd/C; (2) reacting cis-(4-picoline-3-yl)methyl carbamate and benzyl chloride to obtain cis-(1-benzyl-4-methylpiperidine-3-yl)methyl carbamate; (3) performing HOBT catalytic condensation on N-[(3R,4R)-4-methylpiperidine-3-yl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidine-4-amine and cyanoacetic acid to obtain tofacitinib free alkali. The preparation method provided by the invention has easily obtained raw materials, mild reaction conditions, easiness and convenience in operation and high yield, and is suitable for industrial production.

The present invention provides tofacitinib analogues. The analogues contain a compound represented by a formula (I) in the description or a pharmaceutically-acceptable salt of the compound. The invention also discloses a pharmaceutical composition containing the compound represented by the formula I and an application.

The invention belongs to the technical field of medicines, and especially relates to a method for preparing tofacitinib. The method for preparing tofacitinib employs a compound with the structural formula shown as (I), and is characterized in that a compound with the structural formula shown as (III) is prepared from the compound I and a compound with the structural formula shown as (V) or a compound with the structural formula shown as (VI), and the compound III is subjected to a dewatering reaction under the condition of adding a dewatering agent, so that the tofacitinib product with the structural formula shown as (IV) is obtained. Tofacitinib is prepared through two new synthetic routines, the raw materials are cheap and easily obtained, the operation process is simple, the intermediate is easily purified, the total yield is high, the production cost is low, and the method is suitable for industrial amplified production.

The invention discloses a hair growth inducer, which comprises an active ingredient composed of tofacitinib and minoxidil with a mass percentage of 0.1:99.9-99.9:0.1. The hair growth inducing agent provided by the invention, its active ingredient comprises tofacitinib and minoxidil, wherein tofacitinib is a kind of JAK inhibitor, can interact with target cells (such as dermis, epidermis, dermal papilla cells or hair follicles) Cell) specific protein active site selectively binds, inhibits the transmission of cell pathway signals and the synthesis of characteristic cytokines, thereby reducing the symptoms associated with hair loss diseases; Minoxidil is a potassium ion channel opener that can directly relax Vascular smooth muscle has a powerful dilation effect on small arteries, reduces peripheral resistance, promotes the growth of hair follicle cells, and thus regenerates hair; the combination of these two substances synergistically acts on the target protein of target cells and vascular smooth muscle, and inhibits cytokines Synthesis and accelerated blood circulation, in order to achieve a significant effect of promoting hair regeneration.

The invention relates to the technical field of medicines, in particular to compound pharmaceutical composition for treating inflammatory diseases of skin. The compound pharmaceutical composition is characterized in that active ingredients of the compound medicine comprise tofacitinib and crisaborole. The pharmaceutical composition has higher treatment effects and lower use dosage, has remarkablecollaborative treatment effects and can be used for treating inflammatory diseases of skin.

The invention belongs to the technical field of medicine and discloses a tofacitinib crystal form compound and a preparation method thereof. The X-ray powder diffraction spectrum shown by the 2 theta +-0.2 degree diffraction angle shows characteristic diffraction peaks at 2.42 degrees, 3.25 degrees, 4.23 degrees, 5.04 degrees, 6.12 degrees, 7.08 degrees, 8.02 degrees, 9.72 degrees, 10.63 degrees, 12.90 degrees, 14.35 degrees, 15.71 degrees, 17.82 degrees, 18.34 degrees, 19.24 degrees, 22.46 degrees, 24.56 degrees, 26.62 degrees, 30.75 degrees and 32.45 degrees, and the X-ray powder diffraction spectrum obtained by Cu-K alpha ray measurement and shown by the figure I is totally different from the prior art. The tofacitinib crystal form compound has better water solubility and high stability, the preparation method is simple and easy to operate, the medication safety is improved greatly after the compound is prepared into a drug composition, and the compound is very suitable for clinical application.

The invention discloses a preparation method of tofacitinib impurity. A synthetic route is as shown in the specification. The preparation method provided by the invention has the advantages that the synthetic process is simple, the products are easy to separate and purify and the purity of the obtained products is as high as 98.0%. Therefore, the obtained compound I, II in the preparation method can be used for the quality research and process research of related products as impurity reference substances of tofacitinib raw medicinal materials and preparations.

The invention provides tofacitinib tablets and a preparation method thereof. The tablets contain tofacitinib or pharmacologically acceptable salt, a corrigent, an excipient with good water wettability, water insoluble macromolecules and a disintegrant. The preparation method of the tablets comprises the following steps: mixing the tofacitinib or pharmacologically acceptable salt, the excipient with good water wettability, and water insoluble macromolecules to prill; and then adding the corrigent, the disintegrant and a lubricant; and mixing and tabletting the mixture to obtain the tablets. According to the tofacitinib tablets and the preparation method thereof provided by the invention, the tablets are convenient to medicate and quick and efficient to take effect, and can be prepared by means of conventional production equipment; no special demands are put on the equipment; and the preparation process is simple, the stability of the preparation can be guaranteed, and the tablets are conveniently transported and stored and suitable for scaled production.

The invention discloses application of anemoside B4 in preparation of drugs for treating ulcerative colitis. The anemoside B4 can be used for remarkably relieving symptoms of a model mouse suffering from the ulcerative colitis, has an action superior to that of a latest UC Western medicine Tofacitinib and that of a traditional Chinese medicine monomer berberine having a relatively large treatmentprospect to the UC, cannot cause spleen swelling accompanying during treatment on the UC by the two kinds of medicines, has a certain relieving action on the spleen swelling and meanwhile is free of structural impairment to other internal organs. The anemoside B4 is definite in UC treatment effect, low in toxic or side effects and high in safety and is advantageously applied to clinical treatmenton the UC, and problems of the existing medicines that the treatment effect is insufficient, side effects are high, and the toxicity is high are solved.

The invention provides a novel method for synthesizing primary ring cis-4-methyl-3-methylamino-1-benzylpiperidine bis-hydrochloride of tofacitinib. The primary ring cis-4-methyl-3-methylamino-1-benzylpiperidine bis-hydrochloride is made from 3-halogenation-picoline. The novel method includes steps of catalytic Ullman coupling, 3-halogenation-picoline and benzyl halide salifying, hydroboration reagent reduction, salifying and the like to obtain target compounds. The method has the advantages of simple conditions, easily available reagents and operational safety.

The invention discloses a 4-chloro-7H-pyrrolo[2,3-d]pyrimidine synthetic method. A compound is an important intermediate for synthesizing ruxolitinib and tofacitinib as a JAK inhibitor for treating rheumatoid arthritis. The 4-chloro-7H-pyrrolo[2,3-d]pyrimidine synthetic method comprises the following steps of by taking a compound I (4,6-dichloro-5-allyl pyrimidine) as a starting material, performing oxidation reaction on the compound I and ozone to produce a compound II; then performing nucleophilic substitution reaction on the compound II and triethyl orthoformate to produce a compound III; then performing nucleophilic substitution reaction on the compound III and ammonia gas to produce a compound IV; and finally, performing ring closing on the compound IV self in an acid environment to produce a compound V, i.e., 4-chloro-7H-pyrrolo[2,3-d]pyrimidine, wherein a synthetic route is shown as the following formula (described in the description). The synthetic method disclosed by the invention is cheap and available in raw materials, simple and short in synthetic route, low in cost, high in yield and easy in industrial production.

The invention relates to a synthesis method of a JAK inhibitor tofacitinib. The method comprises the steps: with N-[(3R,4R)-1-benzyl-4-methylpiperidin-3-yl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine as a raw material, with formic acid, ammonium formate or hydrazine hydrate as a hydrogen donor, carrying out hydrogenation to remove benzyl to obtain N-[(3R,4R)-4-methylpiperidin-3-yl]-N-methyl-7H-pyrrolo[2,3-d]pyrimidin-4-amine, and then carrying out a reaction with cyanoacetic acid to obtain tofacitinib. Compared with an original synthesis method, the method provided by the invention has the advantages of mild conditions, simple and convenient operation, high yield, low cost and the like, and is suitable for industrialized production.